CenExels Acquisition of Rocky Mountain Movement Disorders Center to...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

CenExels Acquisition of Rocky Mountain Movement Disorders Center to Help Expand Neurology Treatment

Pharma Tech Outlook | Tuesday, January 25, 2022

CenExel RMCR will benefit from the CenExel network's fully integrated and collaborative procedures, such as centralized budgeting, business development, contracting, SOPs, and quality monitoring, to name a few.

Fremont, CA: “The CenExel RMCR team has consistently delivered exceptional clinical trial recruitment and data quality while helping patients with serious neurological conditions achieve their life goals,” comments Tom Wardle, CenExel CEO. Rocky Mountain Movement Disorders Centers' clinical research site activities have been acquired by CenExel Clinical Research. CenExel Rocky Mountain Clinical Research (CenExel RMCR) is a renowned movement disorders research center in Denver, with over 100 clinical trial studies under its belt. Parkinson's disease, Huntington's disease, Essential Tremor, and other movement disorders are among the key indications for CenExel RMCR.

This acquisition expands CenExels reach into other therapeutic indications within Neurology, complementing the company's superior CNS trial expertise. Dr. Rajeev Kumar, the director of CenExel RMCR, has more than 20 years of experience in CNS-focused clinical trial research and medical practice.

The CenExel Centers of Excellence network now includes 13 of the country's most experienced clinical research centers, with a focus on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology. Each CenExel research center has a proven track record of aiding pharmaceutical companies with protocol creation, study design, and Phase I-IV studies to develop new treatments for better patient care.

“The CenExel RMCR team has consistently delivered exceptional clinical trial recruitment and data quality, while helping patients with serious neurological conditions achieve their life goals,” comments Tom Wardle, CenExel CEO. “The partnership with Dr. Kumar and the entire CenExel RMCR team will further elevate the Neurology strength of the CenExel network.”

"We're excited to leverage CenExels site network infrastructure and best practices to expand CenExel RMCRs capabilities and serve more patients impacted by such neurological conditions together." adds Dr. Kumar.

Weekly Brief

Read Also